Skip to Main Content

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Once again, we are reaching for butter pecan. Remember that no prescription is required, so no need to mess with rebates. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day, and please do stay in touch. We treasure the feedback and suggestions in your postcards and telegrams. …

As a U.S. Food and Drug Administration panel meets Wednesday to sort out the ongoing use of booster shots for Covid-19, a new survey by STAT and The Harris Poll finds 6 in 10 Americans have already decided they will get another booster if it’s recommended for them. Just under one-quarter of U.S. adults indicated they will only receive a second booster shot if a new variant arises or there is a surge in Covid-19 cases in their area, and 18% have no plans to get a booster at all, according to the survey, which polled 2,028 U.S. adults between March 25 and 27. The responses reflect ongoing discussions over the role that Covid-19 booster shots should play in combating the coronavirus.


The FDA announced that a GlaxoSmithKline drug for Covid-19 should no longer be used because it is likely ineffective against the Omicron subvariant that now accounts for most U.S. cases, the Associated Press says. The decision was expected, because the FDA had repeatedly restricted the use of the drug, called sotrovimag, in the Northeast and other regions as the BA.2 version of Omicron became dominant. The Centers for Disease Control and Prevention said that BA.2 accounts for 72% of cases sequenced by health authorities. Some experts have warned of a BA.2 surge similar to those that hit European countries, though U.S. case counts have yet to rise.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.